Merck Sharp & Dohme LLC has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS G12D mutant-targeting moiety via a linker reported to be useful for the treatment of cancer.

Genome & Co. has divulged antibody-drug conjugates consisting of antibodies targeting basal cell adhesion molecules (BCAM) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Uppthera Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13)-targeting moiety reported to be useful for the treatment of cancer.

Aleksia Therapeutics Inc. has synthesized cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of breast cancer.

Arc Research Institute and Stanford University have disclosed ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) and/or ENPP3 inhibitors reported to be useful for the treatment of cancer.

Synnovation Therapeutics Inc. has described heterocyclic compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) inhibitors reported to be useful for the treatment of cancer.

Onco3r Therapeutics BV has divulged fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of cancer.

Shandong Luye Pharmaceutical Co. Ltd. has identified salts of CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Lanova Medicines Ltd. has synthesized antibody-drug conjugates (ADCs) comprising antibodies targeting sialyl-Tn antigen (STn) linked to an exatecan derivative through a linker reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of solid cancers and hematological cancers.